Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hair loss drug shows promise in Long-Term trial

NCT ID NCT05041803

Disease control Sponsor: Sun Pharmaceutical Industries, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the long-term safety and effectiveness of a drug called CTP-543 in 407 adults with moderate to severe alopecia areata, a condition that causes patchy or complete hair loss. Participants had already completed 24 weeks of treatment in a previous trial. The goal was to see if the drug remains safe and helps maintain hair regrowth over time. Results will help determine if CTP-543 can be a reliable long-term treatment option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CTP-543 (a drug taken twice daily)
What this could lead to
If successful, this could provide a long-term treatment option for people with severe alopecia areata, helping them regrow and maintain hair.
What could go wrong
This is an extension study, meaning participants already responded well in an earlier trial. It does not prove the drug works for everyone, and long-term side effects are still being monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

407 people

The number who actually took part.

Started

Oct 2021

Finished

Jul 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial Exclusion Criteria: * Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis * Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study medication * Donation of blood at any point throughout the study and for 30 days after last dose of study medication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alopecia areata are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alopecia areata

Contacts and locations

Locations

  • CHU de Bordeaux, Hopital Saint-Andre

    Bordeaux, 33000, France

  • Carpe Diem Centrum Medycyny Estetycznej

    Warsaw, Masovian Voivodeship, 02-661, Poland

  • Centre Hospitalier Universitaire de Toulouse - Hopital Larrey

    Toulouse, 31059, France

  • Clinical Research Center for Hair and Skin Science, Dept of Dermatology, Charité Universitätsmedizin Berlin

    Berlin, 10117, Germany

  • ETG Siedlce

    Siedlce, Masovian Voivodeship, 08-110, Poland

  • ETG Skierniewice

    Skierniewice, Masovian Voivodeship, 96-100, Poland

  • ETG Warszawa

    Warsaw, Masovian Voivodeship, 02-793, Poland

  • Fachklinik Bad Bentheim

    Bad Bentheim, Lower Saxony, 48455, Germany

  • Hopital Saint-Louis - GH De La Rochelle-Re-Aunis

    La Rochelle, 17019, France

  • Hopital de l'Hotel Dieu - CHU de Nantes

    Nantes, 22093, France

  • Hospital 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Clínic de Barcelona

    Barcelona, Barcelona/Cataluña, 08036, Spain

  • Hospital Universitario La Paz

    Madrid, 28046, Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, 28034, Spain

  • Hospital Universitario Reina Sofía

    Córdoba, 14004, Spain

  • Hospital de La Santa Creu i Sant Pau

    Barcelona, 08041, Spain

  • Hospital del Mar

    Barcelona, 08003, Spain

  • Hôpital La Timone-Dermatologie

    Marseille, 13385, France

  • Hôpital Saint Louis, Centre de Santé Sabouraud

    Paris, 75010, France

  • Klinik für Dermatologie und Venerologie, Zentrale Studienkoordination für innovative Dermatologie (ZiD)

    Münster, North Rhine-Westphalia, 48149, Germany

  • Klinik für Dermatologie, Venerologie und Allergologie

    Frankfurt am Main, Hesse, 60590, Germany

  • Klinikum Rechts der Isar, Technische Universität München, Hautklinik

    München, Bavaria, 80802, Germany

  • My Clinic

    Warsaw, 00-144, Poland

  • NZOZ Specjalistyczny Osrodek Dermatologiczny DERMAL

    Bialystok, 15-453, Poland

  • OT.CO Clinic Klinika Osipowicz & Turkowski sp. z o.o

    Warsaw, Masovian Voivodeship, 00-716, Poland

  • Pecsi Tudomanyegyetem Klinikai Kozpont, Bor-, Nemikortani es Onkodermatologiai Klinika

    Pécs, Baranya, 7632, Hungary

  • RCMed Oddzial w Sochaczewie

    Sochaczew, Masovian Voivodeship, 96-500, Poland

  • Royalderm Agnieszka Nawrocka

    Warsaw, 02-962, Poland

  • SZTE AOK Szent-Gyorgyi Albert Klinikai Kozpont, Borgyogyaszati es Allergologiai Klinika

    Szeged, Csongrad-Csanad County, 6720, Hungary

  • Semmelweis Egyetem AOK, Bor-, Nemikortani es Boronkologiai Klinika

    Budapest, Pest County, 1085, Hungary

  • Service de Dermatologie CHRU de Brest - Hopital Morvan

    Brest, Finistere, 29609, France

  • Service de Dermatologie Centre Hospitalier Universitaire de Nice - Hopital Archet 2

    Nice, Provence-Alpes-Côte d'Azur Region, 06202, France

  • Specjalistyczny Gabinet Dermatologiczny s.c.

    Krakow, 30-002, Poland

  • Twoja Przychodnia - Szczecinskie Centrum Medyczne

    Szczecin, 71-500, Poland

  • Twoja Przychodnia Centrum Medyczne Nowa Sol

    Nowa Sól, Lubusz Voivodeship, 67-100, Poland

  • Universitätsklinikum Erlangen, Hautklinik

    Erlangen, Bavaria, 91054, Germany

  • Universitätsklinikum Tübingen Universitäts-Hautklinik

    Tübingen, Baden-Wüttermberg, 72076, Germany

  • Vita Longa Sp.Zo.O

    Katowice, 40-748, Poland

  • WroMedica I. Bielicka, A. Strazalkowska s.c.

    Wroclaw, 51-685, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.